Francesca Sparano

Naples, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Adjuvant immunotherapy in high-risk stage II melanoma: real-world outcomes from a large multicenter retrospective study.

Adjuvant immunotherapy in high-risk stage II melanoma: real-world outcomes from a large multicenter retrospective study.

Journal: Cancer immunology, immunotherapy : CII

Published: April 08, 2026

Clinical activity and safety of nivolumab in combination with ipilimumab in metastatic melanoma: findings from REALIPINIVO, a real-world study.

Clinical activity and safety of nivolumab in combination with ipilimumab in metastatic melanoma: findings from REALIPINIVO, a real-world study.

Journal: Frontiers in immunology

Published: November 03, 2025

Gene-expression signature predicts autoimmune toxicity in metastatic melanoma.

Gene-expression signature predicts autoimmune toxicity in metastatic melanoma.

Journal: Journal for immunotherapy of cancer

Published: June 02, 2025

Melanoma neoadjuvant treatment: review and update of recent trials.

Melanoma neoadjuvant treatment: review and update of recent trials.

Journal: Expert review of anticancer therapy

Published: March 05, 2025

PARP inhibitors in testicular germ cell tumors: what we know and what we are looking for.

PARP inhibitors in testicular germ cell tumors: what we know and what we are looking for.

Journal: Frontiers in genetics

Published: August 13, 2024

A Combined Proteomic and Transcriptomic Signature Is Predictive of Response to Anti-PD-1 Treatment: A Retrospective Study in Metastatic Melanoma Patients.

A Combined Proteomic and Transcriptomic Signature Is Predictive of Response to Anti-PD-1 Treatment: A Retrospective Study in Metastatic Melanoma Patients.

Journal: International journal of molecular sciences

Published: July 23, 2024

Impact of cemiplimab treatment duration on clinical outcomes in advanced cutaneous squamous cell carcinoma.

Impact of cemiplimab treatment duration on clinical outcomes in advanced cutaneous squamous cell carcinoma.

Journal: Cancer immunology, immunotherapy : CII

Published: February 29, 2024

CD39 and LDHA affects the prognostic role of NLR in metastatic melanoma patients treated with immunotherapy.

CD39 and LDHA affects the prognostic role of NLR in metastatic melanoma patients treated with immunotherapy.

Journal: Journal of translational medicine

Published: July 12, 2023

Potential clinical implications of CD4+CD26high T cells for nivolumab treated melanoma patients.

Potential clinical implications of CD4+CD26high T cells for nivolumab treated melanoma patients.

Journal: Journal of translational medicine

Published: May 03, 2023

Sequencing Targeted and Immune Therapy in BRAF-Mutant Melanoma: Lessons Learned.

Sequencing Targeted and Immune Therapy in BRAF-Mutant Melanoma: Lessons Learned.

Journal: Current oncology reports

Published: March 07, 2023

IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab.

IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab.

Journal: Journal of translational medicine

Published: December 12, 2022

Concomitant medication of cetirizine in advanced melanoma could enhance anti-PD-1 efficacy by promoting M1 macrophages polarization.

Concomitant medication of cetirizine in advanced melanoma could enhance anti-PD-1 efficacy by promoting M1 macrophages polarization.

Journal: Journal of translational medicine

Published: September 14, 2022

Showing 1-12 of 21

Last Updated: 09/26/2026